Sugentech Inc. (KOSDAQ:253840)

Market Cap	76.37B -9.2%
Revenue (ttm)	9.87B -1.5%
Net Income	-24.47B
EPS	-1,601.22
Shares Out	15.29M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	517,353
Open	4,985.00
Previous Close	4,955.00
Day's Range	4,960.00 - 5,460.00
52-Week Range	4,310.00 - 8,950.00
Beta	0.53
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About Sugentech

Sugentech Inc. develops and sells in-vitro diagnostic systems and products based on biotechnology, information technology, and nanotechnology in South Korea and internationally. The company offers lab tests, including systems and test items; and COVID-19 tests. It also provides point of care testing analyzers and test items for testing of influenza A/B, antibody test, COVID-19 and flu, SARS-CoV-2, HbA1c, beta-hcg, YSH, T3/T4, and CRP; and digital health and home tests, including mobile health, ovulation, and pregnancy products. The company was ...

• Industry: Medical - Specialties
• Sector: Healthcare
• Founded: 2011
• Employees: 144
• Stock Exchange: KOSDAQ
• Ticker Symbol: 253840

Financial Performance

In 2025, Sugentech's revenue was 9.42 billion, a decrease of -6.74% compared to the previous year's 10.10 billion. Losses were -23.31 billion, 53.5% more than in 2024.